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Utilizing Vaccination for Porcine Circovirus 
Type 2 as a Tool to Aid Elimination of PCV2 
from Swine Populations1,2
M. L. Potter3, S. S. Dritz4, R. A. Hesse4, R. R. R. Rowland4, J. C. 
Nietfeld4, R. Oberst4, S. C. Henry3, L. M. Tokach3, M. Hays4,  
A. Fuller4, B. E. Straw5, and R. O. Bates6
Summary
A total of 928 pigs from the Swine Teaching and Research Centers at Michigan State 
University (MSU) and Kansas State University (KSU) and a Kansas commercial farm 
were used during a 3-year study to determine whether circovirus vaccination influ-
enced porcine circovirus type 2 (PCV2) circulation within a herd and could be used 
as a tool to eliminate PCV2 from PCV2-positive swine herds. Infection with PCV2 
was confirmed in both university herds before circovirus vaccine introduction. After 
vaccination implementation, vaccinated barrows from consecutive groups were serially 
tested for viremia. Follow-up antibody and growth testing with vaccinated and non-
vaccinated pigs was performed at the KSU farm. In a circovirus-vaccinated commercial 
herd, testing of non-circovirus-vaccinated pigs for viremia was completed. Environmen-
tal swab samples were collected from facilities at the KSU and commercial farms for 
PCV2 DNA detection.
Sera from 0 of 9 MSU vaccinated-cohorts and 3 of 10 KSU vaccinated-cohorts had 
detectable PCV2 DNA. From follow-up testing, a PCV2 antibody rise after vaccina-
tion was detected for vaccinated pigs with no detectable antibody rise for non-vacci-
nated pigs. Overall growth rate of non-vaccinated pigs tended (P = 0.07) to increase 
compared with vaccinated pigs. Non-vaccinated pigs became PCV2 viremic at the 
commercial farm. Viral DNA was detected in the environment of the commercial farm 
but not in the KSU facilities.
1 Appreciation is expressed to the Kanas State University Swine Nutrition Team: Drs. Steve Dritz, Mike 
Tokach, Jim Nelssen, Bob Goodband, and Joel DeRouchey; the Kansas State and Michigan State swine 
nutrition and diagnostic medicine/pathology graduate students and undergraduate student employ-
ees; Dr. Kyle Horlen, member of the Rowland Laboratory in the Kansas State Veterinary Diagnostic 
Laboratory; and the Kansas State Swine Research and Teaching Herd Farm Crew, Mark Nelson, Frank 
Jennings, and Lyle Figge, for their assistance with a variety of supportive procedures including planning 
and on-farm data collection, manuscript review, and their continued enthusiasm and willingness to make 
pigs available for sampling purposes.
2 Appreciation is expressed to the American Association of Swine Veterinarians, Kansas State University, 
contributors to the Swine Diagnostic Fund, Michigan State University, and Dr. Brad Thacker (Intervet/
Schering-Plough, Millsboro, DE) for partial funding of this project.
3 Abilene Animal Hospital, PA, Abilene, KS.
4 Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State 
University.
5 Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State 
University.
6 Department of Animal Science, Michigan State University.
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Therefore, circovirus vaccine can affect viral circulation on farms but would need to be 
used in conjunction with other management practices to eliminate PCV2 from most 
swine populations.
Key words: circovirus, disease elimination, PCV2, swine, vaccine
Introduction
Infection with porcine circovirus type 2 (PCV2) can result in a multi-syndrome disease, 
porcine circovirus disease (PCVD).7 Identified in diagnostic laboratory samples in the 
early 1990s, PCV2 has affected most U.S. swine herds. Despite a long history of PCV2 
circulation within the swine population, vaccines against PCV2 have been commer-
cially available only since 2006.8 Initial studies evaluating the effects of circovirus 
vaccination on production parameters in PCV2-affected herds indicate that vaccination 
was effective at reducing finishing phase mortality and increasing pig growth rate.9,10,11 
In single-cohort studies, vaccination with commercial or experimental vaccines against 
PCV2 reduced viremia10,11 and decreased viral shedding in nasal secretions and feces,12,13 
but data evaluating the effects of vaccination on PCV2 viral circulation within a herd 
over time are limited. Our goal was to monitor PCV2 viral circulation in swine herds 
after implementing a circovirus vaccination program for growing pigs. The short-term 
objective of this project was to determine whether circovirus vaccination could be used 
to affect viral circulation within 2 farrow-to-finish herds. The long-term objective of 
the project was to understand whether use of circovirus vaccines over time in PCV2-
positive swine herds could provide a tool to eliminate PCV2 from these herds. 
Procedures
Procedures used in these studies were approved by the Kansas State University and 
Michigan State University Institutional Animal Care and Use Committees.
Herd History. The MSU and KSU Swine Teaching and Research Centers were single-
location farrow-to-finish operations. Pigs were moved through the KSU farm in an 
7 Segalés, J., G. M. Allan, and M. Domingo. 2005. Porcine circovirus diseases. Anim. Health Res. Rev. 
6:119-142.
8 Opriessnig, T., A. R. Patterson, D. M. Madson, N. Pal, and P. G. Halbur. 2009. Comparison of efficacy 
of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection 
model 2-3-months post vaccination. Vaccine 27:1002-1007.
9 K. P. Horlen, S. S. Dritz, J. C. Nietfeld, S. C. Henry, R. A. Hesse, R. Oberst, M. Hays, J. Anderson, and 
R. R. Rowland. 2008. A field evaluation of mortality rate and growth performance in pigs vaccinated 
against porcine circovirus type 2. J Am. Vet. Med. Assoc. 232:906-912.
10 Fachinger, V., R. Bischoff, S. B. Jedidia, A. Saalmüller, and K. Elbers. 2008. The effect of vaccination 
against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine 
26:1488-1499.
11 Kixmöller, M., M. Ritzmann, M. Eddicks, A. Saalmüller, K. Elbers, and V. Fachinger. 2008. Reduction 
of PMWS-associated clinical signs and co-infections by vaccination against PCV2. Vaccine 26:3443-
3451.
12 Fort, M., M. Sibila, A. Allepuz, E. Mateu, R. Roerink, and J. Segalés. 2008. Porcine circovirus type 2 
(PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes 
and geographic origins. Vaccine 26:1063-1071.
13 Fort, M., M. Sibila, E. Pérez-Martín, M. Nofrarías, E. Mateu, and J. Segalés. 2009. One dose of a 
porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-




all-in, all-out manner in nursery, grower, or finisher rooms. In the MSU farm, about 
half of the pigs placed in a nursery, grower, or finisher room were moved in and out at a 
time. Pigs were born (farrowed) at each farm approximately every 4 (MSU) or 5 (KSU) 
wk, which resulted in growing pig populations of about 300 pigs in each age group. 
Both herds were negative for porcine reproductive and respiratory syndrome virus, and 
the MSU herd was negative for Mycoplasma hyopneumoniae (M. hyo). Pigs at the KSU 
farm were vaccinated at weaning for M. hyo (RespiSure-ONE; Pfizer Animal Health, 
New York, NY), which, along with other management procedures, contributed to low 
levels of clinical disease. Prior to the start of our study, both farms had been closed to 
live animal introductions, but semen was introduced from outside sources. In October 
2007, the KSU farm began to bring replacement gilts from an outside source into the 
herd approximately every 9 wk. 
Clinical history. The KSU farm did not have any clinical signs of PCVD noted 
before the baseline testing and subsequent implementation of a circovirus vaccination 
program, although prior to baseline testing, histopathologic evaluation on tissues of 
one pig documented lymphoid depletion lesions consistent with PCVD. The MSU 
farm had evidence of moderate clinical PCVD (10 to 15% nursery mortality) prior to 
baseline testing. 
Phase 1: Baseline testing procedures. In early 2007, a cross-sectional survey was 
conducted of both university herds to verify the presence of PCV2 and to characterize 
patterns of PCV2 infection and seroconversion. At the MSU farm, blood was collected 
from 101 pigs across a total of 5 growing pig populations (6 to 10, 11 to 15, 16 to 20, 
21 to 25, and 26 to 30 wk of age). Within the KSU farm, 141 pigs were sampled across 
5 growing pig populations (4, 9, 14, 19, and 24 wk of age). Serum was pooled (MSU: 
21 pools, and KSU: 27 pools) within age group and analyzed using the Kansas State 
Veterinary Diagnostic Laboratory (KSVDL) PCV2 PCR assay for detection of PCV2 
nucleic acid. Viral template quantities for each serum pool were log10 transformed and 
transformed results were averaged for pools within each age range to characterize the 
changes in viral load. For the detection of PCV2 antibodies, individual serum samples 
were tested using the 96-well format KSVDL PCV2 indirect fluorescent antibody 
(IFA) assay with serial 1:2 dilutions beginning with a 1:20 serum to phosphate-buffered 
saline dilution and ending with a 1:2,560 ratio. The titration endpoint was calculated as 
the reciprocal of the last serum dilution that gave a positive result. 
All IFA titers were log2 transformed to approximate a normal distribution prior to 
descriptive analysis. For samples that did not have antibody detected at the most 
concentrated dilution (1:20), the log2 of 10 was used in the analysis. For samples that 
were strongly positive at the least concentrated dilution (1:2,560), the log2 of 5,120 was 
used. This approach allowed results to be weighted differently than samples with anti-
body detected with a normal level of fluorescence at the 1:20 and 1:2,560 dilutions. 
Infection and antibody profiles obtained from the baseline testing were considered 
when deciding on sampling times for the Phase 2 study on each farm.
Phase 2: Trial procedures. In the spring of 2007, both MSU and KSU initiated circo-
virus vaccination programs. A 2-dose circovirus vaccine (Circumvent PCV; Intervet/
Schering-Plough, Millsboro, DE) was administered as an intramuscular injection  
15
Herd Health
(2 mL per dose) to all growing pigs in each weaning group with 3 to 5 wk between 
vaccine doses. Pigs were weaned and vaccinated with the first dose of circovirus vaccine 
at approximately 3 wk of age at the KSU farm, but weaning age and timing of first vacci-
nation at the MSU farm varied (range: 2 to 6 wk). 
From 2007 through 2008, barrows from consecutive weaning cohorts at the MSU  
(9 groups) and KSU (10 groups) farms were monitored for PCV2 viremia. A minimum 
of 12 barrows per group from different litters were randomly selected, ear-tagged, and 
serially bled at 4 time points: weaning or just before vaccination, entry-to-finishing, 
mid-finishing, and end-of-finishing. After completion of data collection in 2008, indi-
vidual serum samples for pigs with complete serum sets (4 serum samples per pig) were 
tested by the KSVDL PCV2 PCR assay for detection of PCV2 nucleic acid. An aver-
age of 40 cycles was run with a cycle time threshold of 0.05 for classification of PCV2 
nucleic acid-containing (positive) samples.
Phase 3: Follow-up monitoring procedures. Beginning in the spring of 2009, a total of 
372 pigs (186 non-vaccinated control pigs and 186 circovirus-vaccinated pigs) across 
3 weaning groups were used in a Phase 3 growth and PCV2 antibody follow-up study 
at the KSU farm. At the start of the Phase 3 study, the KSU farm had been vaccinat-
ing pigs against PCV2 for the previous 2 years. During that time there had been no 
evidence of clinical disease. A first objective of this follow-up study was to document 
the effects of circovirus vaccination on PCV2 antibody titers and to determine whether 
there was evidence of PCV2 exposure. A second objective of this Phase 3 study was to 
evaluate the effects of circovirus vaccination on growth rate of pigs in the KSU herd. 
Three groups of pigs were used in the Phase 3 study. Groups 1 and 2 had 7 pigs per nurs-
ery pen. A total of 18 barrow pairs (36 pigs; 1 pair in each of 18 pens) for group 1 and 
30 barrow pairs (60 pigs; 1 pair in each of 30 pens) for group 2 were utilized. Within 
a pen, a pair of barrows was selected with one barrow per pair randomly allotted to a 
vaccinated treatment and the pen-mate barrow assigned to the non-vaccinated control 
treatment. Barrows assigned to the vaccinated treatment were injected intramuscularly 
with a 2-dose circovirus vaccine (Circumvent PCV) at approximately 3 and 6 wk of age. 
All other pigs in the weaning group not enrolled in the follow-up study were vaccinated 
with the same 2-dose circovirus vaccine. 
Throughout the entire study, pairs of barrows remained penned together. Barrows 
were individually weighed and bled at 4 time points: d 0 (pre-vaccination), entry-to-
finisher, mid-finishing, and end-of-finishing. From these data, ADG was calculated for 
3 periods: nursery and grower, finisher, and overall nursery to finisher. Removals and 
mortalities were recorded and weighed and their gain and time on test were included in 
performance calculations.
For group 3, 138 barrow or gilt pairs (276 pigs) were randomly allotted to treatments 
(vaccinated or non-vaccinated control) at the time of weaning with procedures similar 
to those used for groups 1 and 2. For group 3, 6 or 8 pigs were assigned to each nurs-
ery pen (3 or 4 pairs within a pen) and all pigs were placed on test. Pigs assigned to the 
vaccinated treatment were injected intramuscularly with a 2-dose circovirus vaccine 
(Circumvent PCV) at approximately 3 and 9 wk of age. Weighing and penning proce-
dures for each pair were similar to those used for groups 1 and 2. A subset of 20 barrow 
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pairs (40 pigs) from 20 different pens distributed throughout the nursery were bled at 
the time of weighing. Pairs of barrows were selected and, within each pair, one barrow 
was randomly assigned to a vaccinated treatment and the pen-mate barrow assigned 
to the non-vaccinated control treatment. For group 3, removals and mortalities were 
recorded and weighed and their gain and time on test were included in performance 
calculations.
Individual serum samples for groups 1, 2, and 3 were tested for PCV2 antibodies using 
the KSVDL IFA assay. Test procedures used were similar to those used in Phase 1; 
however, an initial serum to phosphate-buffered saline dilution of 1:40 was used with 
subsequent serial 1:3 dilutions for group 1, 2, and 3 samples. Testing was performed 
over 7 d (2 d for group 1, 3 d for group 2, and 2 d for group 3), and pairs of pigs were 
balanced across IFA days within each study. 
Group 1, 2, and 3 IFA titers were log3 transformed to approximate a normal distribu-
tion prior to statistical analysis. For samples that did not have antibody detected at the 
most concentrated dilution (1:40), the log3 of 13.3 was used in the analysis, whereas the 
log3 of 262,440 was used for analysis for samples that were strongly positive at the least 
concentrated dilution (1:87,480). This approach allowed these samples to be weighted 
differently than positive samples with normal level fluorescence at 1:40 and 1:87,480.
Group 1, 2, and 3 IFA data were analyzed by repeated measures analysis using the 
GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, Inc., Cary, NC). Fixed 
effects in the model included treatment, time, and their interaction. Group and IFA day 
were used as random effects. Differences between treatments were determined using 
least squares means (P < 0.05). Log3 transformed least squares means were transformed 
back to the original scale for presentation as geometric mean titers (GMT).
Growth data were analyzed using the GLIMMIX procedure in SAS version 9.1.3. The 
interaction with gender and treatment was determined to be non-significant for group 
3, and growth data were pooled across the genders for subsequent analysis of the treat-
ment effect. Thus, growth data for all 3 groups were analyzed using a single model. 
Treatment was a fixed effect and group was included as a random effect. Differences 
between treatments were determined using least squares means (P < 0.05).
Phase 4: Monitoring for PCV2 under commercial conditions. A commercial farm in 
Kansas that was determined to have had severe PCVD before circovirus vaccine became 
available was selected as a herd for an additional monitoring study (Phase 4) because 
of proximity and clinical history. Prior to the introduction of circovirus vaccine, post-
weaning mortality had ranged from 5% to 19%. After implementation of a circovirus 
vaccination program (Circumvent PCV), the herd had less apparent clinical disease 
(mortality: 4 to 9%). The circovirus vaccination program had been in place for a year 
before our Phase 4 study began. In addition to the history of PCV2 infection, porcine 
reproductive and respiratory syndrome virus and M. hyo also contributed to the health 
challenges in the nursery and finishing phases of production. Pigs were weaned from 
a sow farm in western Kansas and moved to eastern Kansas to be placed at a nursery-
finishing site with 2 nursery barns with 4 rooms each and 8 finishing barns. Pigs were 
moved all-in, all-out by nursery room and finishing barn.
17
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A total of 85 pigs (1.7 to 3.1 wk of age) from a 1,100-pig weaning group were ear-tagged 
and bled just prior to weaning. These 85 pigs were not vaccinated against PCV2 and 
were monitored for 9 wk. All other pigs in the weaning group were vaccinated accord-
ing to standard farm protocol with a 2-dose circovirus vaccine (Circumvent PCV). The 
85 non-vaccinated sentinel pigs were initially penned in 4 pens in the nursery room 
that also contained pens of circovirus-vaccinated pigs. If pigs were removed from their 
initial pens because of illness or injury, they were moved to a sick pig pen but were 
still monitored. After approximately 8 wk in the nursery, pigs were moved to a single 
finisher barn at the same farm location and were placed in pens according to their vacci-
nation status. Pigs were bled approximately every 3 wk for a total of 4 sampling times 
(sampling time age ranges: 1.7 to 3.1, 4.9 to 6.3, 7.9 to 9.3, and 10.9 to 12.3 wk of age). 
The objective of this monitoring effort was to determine whether non-vaccinated pigs 
housed in barns with pigs vaccinated against PCV2 became viremic with PCV2 after 
circovirus vaccine was used in the herd for a year.
Serum samples were pooled (5 samples per pool) within age range and were analyzed by 
the KSVDL PCV2 PCR assay for presence of PCV2 nucleic acid. Genotype of PCV2 
(PCV2a or PCV2b) was determined for samples with detectable PCV2 nucleic acid.
Phase 5: Monitoring for PCV2 in the environment of swine barns. As pigs involved 
in all previous phases of this study were exposed to different environments and pigs 
over time, we wanted to determine whether documentable sources of PCV2 exposure 
existed. The objective for this phase of monitoring was to demonstrate applicability of 
swabbing and PCV2 PCR testing as a method for monitoring PCV2 levels on environ-
mental surfaces in swine production facilities. 
Swab samples were collected from the nursery and finisher rooms at both the KSU farm 
and the commercial farm in eastern Kansas that was used in the Phase 4 study. Cotton 
swabs were used to sample the floor slats, gating, waterers, feeders, fans and heaters in 
the nursery or finishing rooms. Swabs were placed in vials containing enriched media. 
For each farm, samples were pooled within nursery or finishing production phases  
(2 KSU nursery or finishing pools and 16 commercial farm nursery or finishing pools). 
A uniform amount of this pooled suspension was tested by KSVDL PCV2 PCR for 
detection of PCV2 nucleic acid. 
Results 
Phase 1. Baseline PCV2 IFA testing of the serum collected from pigs from the MSU 
herd demonstrated that passively acquired antibody declined by 15 wk of age (Figure 
1). Higher levels of antibody were apparent in pigs 16 to 20 wk of age or older. PCV2 
nucleic acid was detected by PCR in serum samples from pigs 11 to 15 wk of age and 
older (Figure 2). 
In the baseline analysis of the KSU herd (Phase 1), passively acquired antibody in grow-
ing pigs declined by 19 wk of age with higher levels of antibody detected following this 
decline (Figure 3). Viremia was detectable only in populations consisting of pigs that 
were 19 and 24 wk of age (Figure 4). The 19-wk-old pigs were viremic but did not have 
antibody levels suggestive of seroconversion. 
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Phase 2. After introduction of circovirus vaccination, PCV2 PCR testing of serum 
samples collected over time from 9 MSU and 10 KSU cohort groups showed a different 
infection pattern on each farm compared with baseline PCR profiles. From the MSU 
farm, PCV2 PCR testing on sera collected from 86 barrows at 4 sampling points (pre-
vaccination, entry-to-finishing, mid-finishing, and end-of-finishing) failed to detect 
PCV2 nucleic DNA (Table 1). 
From the KSU farm, testing by PCV2 PCR on serum samples from 111 barrows failed 
to detect nucleic acid (PCV2 PCR negative) in samples collected at any time from pigs 
in groups 1, 2, 4, 7, 8, 9, and 10 (Table 2). Serum samples with detectable PCV2 DNA 
(PCV2 PCR positive) were found in group 3 (10%, 1/10 samples from mid-finishing), 
group 5 (25%, 3/12 samples from weaning; 25%, 3/12 samples from entry-to-finishing; 
8.3%, 1/12 samples from mid-finishing; and 8.3%, 1/12 samples from end-of-finishing), 
and group 6 (8.3%, 1/12 samples from entry-to-finishing). For serum samples with 
detectable DNA, viral template quantity ranged from 5 to 379 viral template copies per 
reaction. In only 1 (group 5) of the 10 groups (10%) did a pig remain viremic for longer 
than 1 testing interval. Overall, no PCV2 viral DNA was detected in samples from 7 of 
the 10 groups (70%) monitored over a time period of greater than 1 year. 
Phase 3. After 2 years of vaccinating growing pigs against PCV2 at the KSU farm, 
subsamples of pigs were allocated to a circovirus-vaccinated treatment or a non-vacci-
nated control treatment in a growth and PCV2 antibody follow-up study (Phase 3). 
An interaction (P < 0.001) between treatment and time occurred for antibody level 
(Table 3). With the exception of the initial bleed (d 0; during the wk of weaning) when 
control and vaccinated pig antibody levels were similar (P = 0.41), vaccinated pigs 
had increased (P < 0.001) PCV2 antibody levels compared with controls at all other 
sampling times. The magnitude of the antibody responses varied over time for control 
and vaccinated pigs, as did the pattern of antibody production or decay. By the time the 
pigs were placed into the finisher, control pig antibody levels had declined (P < 0.001) 
compared with their respective d 0 levels; however, control pig antibody levels remained 
similar (P ≥ 0.61) throughout the finishing period. In contrast, compared with their 
respective d 0 antibody levels, vaccinated pigs had an increase (P < 0.001) in PCV2 
antibody titer by the time of entering the finisher, which decreased (P < 0.001) by each 
of the subsequent sampling points. 
During the nursery and grower periods, vaccinated pigs had decreased (P = 0.005; 
Table 4) ADG compared with non-vaccinated control pigs. Vaccinated and control 
pigs had similar (P = 0.30) finishing ADG, although growth rates for vaccinated pigs 
continued to be numerically less than control pig growth rates. Overall, a tendency  
(P = 0.07) was observed for vaccinated pigs to have decreased ADG compared with 
control pigs. These growth rate differences resulted in control pigs entering the finisher 
2.6 lb heavier (P = 0.03) than vaccinated pigs. When pigs were taken off test at the end 
of the finishing period, control pigs had a numeric weight advantage (P = 0.16) of 4.4 lb 
over vaccinated pigs. 
Phase 4. Results obtained from the commercial farm with a 1-year history of circovirus 
vaccination differed from those observed in the KSU farm. From a serial sampling of 85 
non-vaccinated sentinel pigs, no PCV2 DNA was detected in the weaning pools (0/17 
pools; Table 5). In contrast, PCV2 nucleic acid was detected in pooled samples at each 
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of 3 subsequent sampling ages (4.9 to 6.3 wk of age: 1/17 pools; 7.9 to 9.3 wk of age: 
6/16 pools; and 10.9 to 12.3 wk of age: 12/16 pools). Genotype was reported for each 
pool. PCV2a was detected in all but 1 pool (4.9 to 6.3 wk of age: 1/17 pools; 7.9 to 9.3 
wk of age: 6/16 pools; and 10.9 to 12.3 wk of age: 11/16 pools), but PCV2b was not 
detected in any of the pools until 10.9 to 12.3 wk of age (2/16 pools). 
Phase 5. Environmental swabbing and testing by PCV2 PCR (Figure 5) detected 
PCV2 DNA in samples from 8 commercial nursery and 8 commercial finisher barns. 
In contrast, the presence of PCV2 DNA was not detected by PCV2 PCR testing of 
environmental swab samples from the KSU farm.
Discussion
This was a first study to evaluate the effects of circovirus vaccination on viral circulation 
at the herd level. Our study was designed to begin to evaluate the hypothesis that circo-
virus vaccination programs in herds would affect viremia and subsequent viral shedding 
into the environment. Over time, a reduction in environmental contamination coupled 
with continued use of circovirus vaccine to build immunity in growing pigs prior to 
viral exposure would aid derivation of PCV2-free herds. 
The MSU and KSU herds and management served as models for commercial multisite 
swine production systems. Based on the Phase 1 baseline testing, PCV2 was detected 
in both swine populations, although viremia was not increased until after the nursery 
period. This testing provided evidence for primarily horizontal rather than vertical 
transmission. Both herds had PCV2-viremic pigs during finishing and showed evidence 
that pigs likely seroconverted after the documented time for onset of viremia (Figures 1, 
2, 3, and 4). 
Although both farms had evident viral circulation during finishing, the MSU pigs expe-
rienced an earlier onset of viremia than the KSU pigs. Both herds were considered good 
models in which to monitor the effects of circovirus vaccination long-term because 
baseline results from both non-vaccinated populations indicated viral presence and 
seroconversion-supporting antibody profiles.
Circovirus vaccination programs were started in each herd in the spring of 2007, and 
monitoring of barrows from each farrowing group began. In the MSU herd, viremia 
was not detected in serum collected at any sampling point from circovirus-vaccinated 
barrows (Table 1). During the same time, there were no reports of clinical PCVD from 
the farm, but some pigs may have become transiently viremic between sampling points; 
however, the MSU farm baseline testing indicated onset of viremia early in the finishing 
phase and infection appeared to be detectable in a portion of the population through-
out finishing. Thus, the MSU vaccinated pig PCR data demonstrate that vaccination 
had an effect on the viral circulation within this farm by either shortening the duration 
of viremia or preventing it altogether.
In the KSU herd, 3 groups had at least 1 pig with detectable PCV2 DNA in the serum. 
These groups (3, 5, and 6; Table 2) were not consecutive groups, nor were the ages at 
the time of detectable viremia consistent among groups. In addition, only 1 group had 
pigs testing positive for PCV2 at more than 1 sampling point. Although the viral load 
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levels between sampling points were not known, the PCV2 viral loads detected in the 
positive serum samples among the 4 bleeding times were 379 template copies per reac-
tion or less. Additionally, none of the viremic vaccinated pigs or their group-mates had 
been identified as PCVD suspects. Evidence of PCV2 problems was restricted to PCR 
detection of transient viremia. Although PCV2 was intermittently detected among 
vaccinated pigs, because no naïve pigs were in the population, the virus was not able to 
transmit readily, propagate within groups, and establish widespread infection within 
the herd; therefore, the KSU herd results indicate immunization by circovirus vacci-
nation affected viral circulation by controlling the spread of virus and shortening the 
duration of viremia or by preventing the infection entirely.
The follow-up study (Phase 3) was performed at the KSU farm to verify that circovirus 
vaccination had affected within-farm viral circulation patterns and to determine the 
farm’s new PCV2 status. Results indicate a change in the herd PCV2 antibody profile. 
Pigs for this follow-up study were born primarily from dams that were vaccinated 
against circovirus as weaned pigs; however, gilts or sows were not vaccinated against 
circovirus prior to breeding or during gestation. Before vaccine introduction into the 
herd, pigs had antibody decay until mid-finishing followed by high levels of antibody in 
late-finishing, so the pattern after 2 years of continuous vaccination was different. Anti-
body levels at the time of weaning were similar and low for pigs assigned to the control 
or vaccinated treatments (Table 3). After vaccination, vaccinated pigs had a rise in anti-
body by the beginning of the finishing period that then decreased throughout finishing. 
In contrast, control pigs had decay in antibody levels through the beginning of finishing 
and never had a rise in antibody levels. The lack of antibody rise suggests that control 
pigs were not exposed to the PCV2 virus during the time period for sampling. Residual 
PCV2 virus shed from previously infected pigs and present in the environment did not 
appear to stimulate an immune response in these control pigs, nor did it appear that 
there was exposure to PCV2 virus transmitted from vaccinated but infected pigs within 
the groups. These follow-up KSU results indicate that the virus had either been elimi-
nated from the herd and farm facilities, or had fallen below the threshold that could 
trigger stimulation of the immune system.
Growth rate has been used as an indicator of disease and was therefore included as a 
response for this study. In our study, circovirus vaccination negatively affected growth 
rate during the nursery and grower periods (Table 4). This resulted in vaccinated pigs 
2.6 lb lighter than non-vaccinated control pigs at the beginning of the finishing period. 
During the finisher phase and for the overall study, vaccinated pigs had numerically 
reduced ADG compared with control pigs. At the time pigs were taken off test, control 
pigs had a 4.4 lb numeric weight advantage compared with vaccinated pigs, but the lack 
of positive growth rate response due to vaccination may be explainable by low or no 
natural PCV2 challenge in the KSU herd. 
In our study, vaccinated pigs during finishing did not demonstrate greater ADG 
compared with non-vaccinated control pigs. Vaccinated pigs were not able to compen-
sate for or overcome the negative effects of vaccination in the nursery. Thus, the immu-
nity built in the nursery and grower period did not provide any benefit during finishing 
because PCV2 was not present as a challenge to the immune system of the pigs. There-
fore, the lack of serologic evidence for PCV2 exposure coupled with the tendency for 
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vaccinated pigs to have poorer overall growth performance than control pigs suggests 
that PCV2 was not a pathogenic threat for growing pigs in the KSU herd during the 
follow-up testing. 
The results that indicated PCV2 was no longer an apparent natural challenge for pigs 
in the KSU farm could not be replicated in a commercial farm in Kansas despite both 
farms having implemented long-term circovirus vaccination programs. At the time the 
data were collected, the commercial farm had been continuously vaccinating pigs for  
1 year—slightly less time than the KSU farm. Clinical disease had decreased during the 
time the vaccine was being used in the commercial herd. The commercial farm moved 
pigs all-in, all-out from their nursery and finisher rooms and used a disinfectant similar 
to that of the KSU farm; however, the period of downtime between batches of pigs 
for cleaning and disinfection of rooms was longer at the KSU farm compared with the 
commercial farm. 
In the commercial farm, the non-vaccinated pigs did become viremic after movement 
into the nursery (Table 5) and exhibited clinical signs of PCVD. The clinical disease in 
these pigs was apparent even though they constituted a relatively low percentage of the 
population, and herd immunity did not appear to prevent propagation of the infec-
tion; therefore, the belief that housing environment contributed a significant source 
of PCV2 virus in this population led us to perform the environmental evaluation. We 
acknowledge that pig-to-pig transmission from viremic pigs could also play a role in 
the dynamics of the infection, but we believe this was less likely. At each time point, 
more serum pools had detectable DNA, which indicated that more pigs were becoming 
infected. In addition, PCV2a was detected first, followed by PCV2b, so the infection 
profile also changed over time. Whether this differential pattern has biologic signifi-
cance is yet to be determined.
To understand why non-vaccinated pig results differed between the KSU herd and the 
commercial farm, it was important to identify sources of viral exposure. Pigs at both 
farms were seemingly weaned free of PCV2, implicating PCV2 in the environment as a 
primary source of exposure. Swabs were collected in all nursery and finishing rooms at 
the commercial farm. Nursery and finishing rooms at the KSU farm that had housed 
study pigs at some point through the 3-year study were also sampled. Although PCR 
detection of PCV2 nucleic acid does not provide any information about whether the 
viral material is infectious, it does allow measurement of environmental viral loads that 
could potentially contain infectious material. 
In the commercial facility, PCV2 DNA was found in every room and barn. In contrast, 
at the KSU farm, PCV2 nucleic acid was not detected in either the nursery or finishing 
facility. Although the infectivity status of the PCV2 DNA detected at the commercial 
site was not known, any residual infectious material present in the environment could 
explain why non-vaccinated pigs placed in this facility became viremic shortly after 
movement into the facility. Complete inactivation of PCV2 was difficult by disinfec-
tion under laboratory conditions.14 Therefore, in our study, with viral material detected 
in the environment, some infectious virus likely remained. Further investigation of this 
14 Royer, R. L., P. Nawagitgul, P. G. Halbur, and P. S. Paul. 2001. Susceptibility of porcine circovirus type 
2 to commercial and laboratory disinfectants. J. Swine Health Prod. 9:281-284.
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environmental virus-based route of transmission is warranted to determine the impor-
tance of this potential risk.
In conclusion, results from this 3-year investigation indicate that circovirus vaccination 
did affect viral circulation in swine herds. Success in lowering levels or eliminating the 
virus as a pathogenic threat was achieved at a university research herd, but other expo-
sure risk factors, such as residual PCV2 in the environment, appeared under commer-
cial conditions and inhibited viral elimination efforts. Therefore, circovirus vaccine 
provides a tool to affect viral circulation on farms but needs to be used in conjunction 
with other management practices to eliminate PCV2 from most swine populations.
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Table 1. Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially collected from barrows across 9 consecutive weaning groups enrolled in a post-
circovirus-vaccination implementation monitoring program at the Michigan State 
University Swine Teaching and Research Center1
Sampling2
Item Pigs, no.3









Interval, wk4 --- 6.1 14.0 17.1
PCV2 DNA detected5 no no no no
Group 2 9
Interval, wk4 --- 7.1 15.1 18.0
PCV2 DNA detected5 no no no no
Group 3 9
Interval, wk4 --- 5.9 12.0 18.0
PCV2 DNA detected5 no no no no
Group 4 9
Interval, wk4 --- 7.0 13.0 18.1
PCV2 DNA detected5 no no no no
Group 5 11
Interval, wk4 --- 5.9 12.9 16.9
PCV2 DNA detected no no no no
Group 6 10
Interval, wk4 --- 6.0 11.1 18.0
PCV2 DNA detected5 no no no no
Group 7 10
Interval, wk4 --- 8.1 15.0 20.0
PCV2 DNA detected5 no no no no
Group 8 9
Interval, wk4 --- 6.3 13.1 18.0
PCV2 DNA detected5 no no no no
Group 9 9
Interval, wk4 --- 6.0 13.0 18.0
PCV2 DNA detected5   no no no no
1 A total of 86 barrows (4 samples per barrow) were serially bled and serum was analyzed by PCR for detectable 
PCV2 DNA. All pigs were vaccinated intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Inter-
vet/Schering-Plough Animal Health, Millsboro, DE) after the d 0 blood sample was collected (during the week of 
weaning).
2 Sampling points were during weaning week (d 0; single pre-vaccination serum sample), after entry to the finisher, 
during mid-finishing, and at the end of the finishing period. 
3 An average of 12 barrows were randomly selected across 9 consecutive farrowing groups, ear-tagged, and moni-
tored for their lifetime. Only serum samples from barrows with complete serum sets (4 serum samples per pig) 
were tested by PCR for detectable PCV2 nucleic acid. Number of pigs reported in the table represents the number 
of pigs with complete serum sets.
4 Interval indicates the amount of time in weeks that had elapsed since the previous sampling point. The d 0 sample 
was collected during weaning week.
5 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid. Results are reported as 
“yes” if a sample had detectable PCV2 nucleic acid for the indicated group and sampling point, and “no” if no 
samples had detectable PCV2 nucleic acid.
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Table 2. Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially collected from barrows across 10 consecutive weaning groups enrolled in a post-
circovirus-vaccination implementation monitoring program at the Kansas State Univer-
sity Swine Teaching and Research Center1
Sampling2
Item Pigs, no.3









Interval, wk4 --- 8.7 15.0 21.9
PCV2 DNA detected5 no no no no
Group 2 10
Interval, wk4 --- 9.9 14.9 20.0
PCV2 DNA detected5 no no no no
Group 3 10
Interval, wk4 --- 9.3 14.4 19.1
PCV2 DNA detected5,6 no no yes no
Group 4 8
Interval, wk4 --- 10.1 14.9 20.0
PCV2 DNA detected5 no no no no
Group 5 12
Interval, wk4 --- 9.9 15.0 19.9
PCV2 DNA detected5,6 yes yes yes yes
Group 6 12
Interval, wk4 --- 10.3 15.3 19.8
PCV2 DNA detected5,6 no yes no no
Group 7 12
Interval, wk4 --- 10.2 14.0 19.5
PCV2 DNA detected5 no no no no
Group 8 12
Interval, wk4 --- 9.7 14.7 17.1
PCV2 DNA detected5 no no no no
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Table 2. Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 
serially collected from barrows across 10 consecutive weaning groups enrolled in a post-
circovirus-vaccination implementation monitoring program at the Kansas State Univer-
sity Swine Teaching and Research Center1
Group 9 12
Interval, wk4 --- 9.7 15.0 19.6
PCV2 DNA detected5 no no no no
Group 10 12
Interval, wk4 --- 10.3 14.9 20.3
PCV2 DNA detected5   no no no no
1 A total of 111 barrows (4 samples per barrow) were serially bled and serum was analyzed by PCR for detectable 
PCV2 DNA. All pigs were vaccinated intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Inter-
vet/Schering-Plough Animal Health, Millsboro, DE) after the d 0 blood sample was collected (during the week of 
weaning).
2 Sampling points were during weaning week (d 0; single prevaccination serum sample), after entry to the finisher, 
during mid-finishing, and at the end of the finishing period. 
3 An average of 12 barrows were randomly selected across 10 consecutive farrowing groups, ear-tagged, and moni-
tored for their lifetime. Only serum samples from barrows with complete serum sets (4 serum samples per pig) 
were tested by PCR for detectable PCV2 nucleic acid. Number of pigs reported in the table represents the number 
of pigs with complete serum sets.
4 Interval indicates the amount of time in weeks that had elapsed since d 0 (day of vaccination). The d 0 sample was 
collected during weaning week and was collected before the vaccine was administered.
5 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid. Results are reported as 
“yes” if a sample had detectable PCV2 nucleic acid for the indicated group and sampling point, and “no” if no 
samples had detectable PCV2 nucleic acid.
6 Viral template quantities ranged from 5 to 379 template copies per reaction across serum samples with detectable 
PCV2 nucleic acid. Within group 5 pigs and 2 barrows had serum samples with detectable nucleic acid at more 













Table 3. Effect of circovirus vaccination and time on indirect fluorescent antibody (IFA) geometric mean titer (GMT) in pigs produced at a farm that had been 
vaccinating growing pigs against porcine circovirus type 2 (PCV2) continuously for 2 years1
Treatment2




















Samples, no. 68 68 68 68 68 66 66 66 ---
GMT3 35.9a 15.2b 14.8b 13.6b 43.6a 52789.3c 13841.2d 3729.8e <0.001
a,b,c,d,e Means without a common superscript letter differ (P < 0.05). 
1 A total of 136 barrows (68 control and 68 vaccinated pigs) across 3 farrowing groups were ear-tagged and monitored from weaning through finishing at the Kansas State University Swine Teaching and 
Research Center. Pigs were serially bled on d 0 (within a wk of weaning), after entering the finisher (time elapsed since d 0 range: 8.4 to 8.9 wk), mid-finishing (time elapsed since d 0 range: 13.4 to 13.9 wk), 
and at the end of the finishing period (time elapsed since d 0 range: 18.0 to 19.4 wk). Antibody levels against PCV2 were determined by IFA testing on individual serum samples. Individual pig IFA titer 
data were log3 transformed and were analyzed by repeated measures analysis using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, Inc., Cary, NC). Fixed effects in the model included treat-
ment, time, and their interaction. Group and IFA day were included as random effects. 
2 Treatments were non-vaccinated control or vaccinated. Vaccinated pigs were injected intramuscularly with 2 doses (2 mL per dose) of Circumvent PCV (Intervet/Schering-Plough Animal Health, Mills-
boro, DE) after the d 0 blood sample was collected (during the week of weaning).
3 Geometric mean titers were calculated by taking the mean of the log3 transformed IFA titer values then converting the resulting transformed mean back to the original scale for presentation.
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Table 4. Effect of circovirus vaccination on growth rate of pigs produced at a farm that 
had been vaccinating growing pigs against porcine circovirus type 2 (PCV2) continu-
ously for 2 years1
Treatment2
Item Control Vaccinate SEM Probability, P <
Pigs started on test, no. 186 186 --- ---
ADG, lb
Nursery-grower3 1.24 1.18 0.013 0.005
Finisher4 2.41 2.39 0.029 0.30
Overall5 1.88 1.85 0.023 0.07
Weight, lb
d 0 13.9 14.0 0.44 0.97
Entry-to-finishing 89.0 86.4 1.99 0.03
End-of-finishing (off test) 262.8 258.4 5.33 0.16
1 A total of 372 weanling pigs (186 control and 186 vaccinated pigs) across 3 farrowing groups were ear-tagged and 
monitored from weaning through finishing at the Kansas State University Swine Teaching and Research Center. 
Pigs were individually weighed on d 0 (within the weaning week and the day of vaccination), after entering the 
finisher, and at the end of the finishing period to calculate ADG. Growth and on-test time data from mortali-
ties and removed pigs were included in growth and period length calculations. Individual pig growth data were 
analyzed using the GLIMMIX procedure in SAS version 9.1.3 (SAS Institute, Inc., Cary, NC). The interaction 
with gender and treatment was determined to be non-significant for group 3, and growth data were pooled across 
the genders for subsequent analysis. Growth data for all 3 groups were analyzed using a model that included treat-
ment as a fixed effect and group as a random effect.
2 Treatments were non-vaccinated control or vaccinated. Vaccinated pigs were injected intramuscularly with 2 
doses (2 mL per dose) of Circumvent PCV (Intervet/Schering-Plough Animal Health, Millsboro, DE).
3 Nursery-grower ADG and period length include data from mortalities and removed pigs. The nursery period 
length did not differ (P = 0.15) between control (59.7 ± 1.48 d) and vaccinated (59.1 ± 1.48 d) pigs.
4 Finisher ADG and length include data from mortalities and removed pigs. The number of days for the finisher 
period did not differ (P = 0.94) between control (71.7 ± 1.13 d) and vaccinated (71.6 ± 1.14 d) pigs.
5 Overall ADG and length include data from mortalities and removed pigs. The number of days for the overall trial 
did not differ (P = 0.96) between control (132.1 ± 2.67 d) and vaccinated (132.1 ± 2.67 d) pigs.
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Table 5. Detection of porcine circovirus type 2 (PCV2) nucleic acid in serum samples 




1.7 to 3.1  
(wean wk) 4.9 to 6.3 7.9 to 9.3
10.9 to 
12.3
Pig survival, % 100.0 97.6 91.8 91.8
Interval, wk3 --- 3.2 6.2 9.2
PCV2 PCR results
Pools for PCR, no.4 17 17 16 16
PCV2 DNA detected5,6 no yes yes yes
Pools with detectable PCV2 DNA, % 0 5.9 37.5 75.0
1 A total of 85 pigs were serially bled and serum was analyzed by PCR for detectable PCV2 DNA. Pigs were not 
vaccinated for PCV2 at any time during this monitoring period on this commercial farm.
2 Pigs were bled initially during the wk of weaning when pig ages ranged from 1.7 to 3.1 wk of age. Pigs were serially 
bled every 3 wk (on average) thereafter until pigs were 10.9 to 12.3 wk of age. 
3 Interval indicates the amount of time in weeks that had elapsed since the initial sampling point. The initial 
sample was collected during weaning week.
4 A total of 5 serum samples were included in a single pool for testing by PCV2 PCR.
5 All serum samples were individually tested by PCR for presence of PCV2 nucleic acid. Results are reported as 
“yes” if a sample had detectable PCV2 nucleic acid for the indicated group and sampling point, and “no” if no 
samples had detectable PCV2 nucleic acid.




















Figure 1. Characterization of the porcine circovirus type 2 (PCV2) antibody profile of 
the Michigan State University (MSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
At the MSU farm, a total of 101 pigs were sampled across 5 growing pig populations (6 to 
10, 11 to 15, 16 to 20, 21 to 25, and 26 to 30 wk of age) using a cross-sectional design. Serum 
samples from individual pigs were tested by the Kansas State University Veterinary Diagnostic 
Laboratory PCV2 indirect fluorescent antibody (IFA) assay for detection of PCV2 antibodies. 
All IFA titers were log2 transformed to approximate a normal distribution prior to descriptive 
analysis. Resulting transformed means were transformed back to the original scale for presenta-
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Figure 2. Characterization of the porcine circovirus type 2 (PCV2) infection profile of 
the Michigan State University (MSU) Swine Teaching and Research Center herd prior to 
implementation of a circovirus vaccination program. 
Serum was pooled (MSU: 21 pools) within age group and analyzed using the Kansas State 
University Veterinary Diagnostic Laboratory PCV2 PCR assay for detection of PCV2 nucleic 
acid. Pooled results were log10 transformed and transformed results were averaged within age 


















Figure 3. Characterization of the porcine circovirus type 2 (PCV2) antibody profile of the 
Kansas State University (KSU) Swine Teaching and Research Center herd prior to imple-
mentation of a circovirus vaccination program.
At the KSU farm, a total of 141 pigs were sampled across 5 growing pig populations (4, 9, 
14, 19, and 24 wk of age) using a cross-sectional design. Serum samples from individual pigs 
were tested by the Kansas State University Veterinary Diagnostic Laboratory PCV2 indirect 
fluorescent antibody (IFA) assay for detection of PCV2 antibodies. All IFA titers were log2 
transformed to approximate a normal distribution prior to descriptive analysis. Resulting trans-
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Figure 4. Characterization of the porcine circovirus type 2 (PCV2) infection profile of the 
Kansas State University (KSU) Swine Teaching and Research Center herd prior to imple-
mentation of a circovirus vaccination program.
Serum was pooled (KSU: 27 pools) within age group and analyzed using the Kansas State 
University Diagnostic Laboratory PCV2 PCR assay for detection of PCV2 nucleic acid. Pooled 
results were log10 transformed and transformed results were averaged within age ranges to char-





















































Figure 5. Detection of porcine circovirus type 2 (PCV2) nucleic acid in the environment 
of nursery and finisher facilities at the Kansas State University (KSU) Swine Teaching and 
Research Center and a commercial farm. Effect of farm and nursery location on environ-
mental PCV2 DNA detection (A) and effect of farm and finisher location on environmen-
tal PCV2 DNA detection (B) are shown below.
Porcine circovirus type 2 (PCV2) PCR results for environmental swabs of Farm A (KSU 
farm) and Farm B (commercial farm) nursery and finisher locations. Cycle time (Ct) values are 
reported as 0.0 (no PCV2 DNA detected) or greater than 0.0 (PCV2 DNA detected) with the 
lower positive Ct values indicative of more PCV2 viral DNA.
